Security
Personalis, Inc. Common Stock · PSNL
PSNLNASDAQCommon stockCurrentCIK 1527753Updated Nov 2, 2026
PSNL price & chart
Loading TradingView…
NASDAQ:PSNL on TradingView ↗About the company
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
In the news
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus ↗
Shareholder Alert: Ademi LLP investigates whether Personalis, Inc. is obtaining a Fair Price for Public Shareholders ↗
Smart Oncology: 5 Stocks Chasing the $317B Prize News provided by USA News Group Dec 31, 2025, 07:25 ET Share this article Share to X Share this article Share to X Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC , Dec. 31, 2025 /PRNewswire/ -- The precisio ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 242,839,000Source | 239,887,000Source | 312,135,000Source | 258,680,000Source | 185,502,000Source | 325,395,000Source | 273,308,000Source | 195,276,000Source | 334,164,000Source | 270,268,000Source | 225,099,000Source | 292,700,000Source |
| Property, Plant and Equipment, NetUSD | 47,003,000Source | 50,231,000Source | 48,567,000Source | 45,812,000Source | 52,662,000Source | 48,438,000Source | 47,986,000Source | 54,529,000Source | 44,815,000Source | 48,274,000Source | 57,366,000Source | 61,935,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 49,973,000Source | 75,800,000Source | 93,968,000Source | 53,374,000Source | 47,747,000Source | 73,594,000Source | 71,001,000Source | 43,981,000Source | 124,245,000Source | 91,415,000Source | 56,984,000Source | 89,128,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 14,376,000Source | 13,474,000Source | 15,102,000Source | 9,952,000Source | 12,921,000Source | 13,022,000Source | 10,973,000Source | 11,345,000Source | 16,203,000Source | 8,140,000Source | 17,730,000Source | 16,642,000Source |
| Assets, CurrentUSD | 174,402,000Source | 170,277,000Source | 245,052,000Source | 193,343,000Source | 113,103,000Source | 258,198,000Source | 206,422,000Source | 120,439,000Source | 267,951,000Source | 203,015,000Source | 146,744,000Source | 199,699,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,855,000Source | 4,663,000Source | 7,654,000Source | 4,724,000Source | 4,046,000Source | 5,028,000Source | 4,838,000Source | 4,908,000Source | 5,651,000Source | 3,927,000Source | 4,361,000Source | 6,808,000Source |
| Operating Lease, Right-of-Use AssetUSD | 15,249,000Source | 16,816,000Source | 14,860,000Source | 15,654,000Source | 17,166,000Source | 14,957,000Source | 16,055,000Source | 17,515,000Source | 15,118,000Source | 16,453,000Source | 17,852,000Source | 26,480,000Source |
| Other Assets, NoncurrentUSD | 6,185,000Source | 2,563,000Source | 3,656,000Source | 3,871,000Source | 2,571,000Source | 3,802,000Source | 2,845,000Source | 2,793,000Source | 6,280,000Source | 2,526,000Source | 3,137,000Source | 4,586,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 71,424,000Source | 73,126,000Source | 76,974,000Source | 67,851,000Source | 73,230,000Source | 70,630,000Source | 65,963,000Source | 74,582,000Source | 72,979,000Source | 67,311,000Source | 95,658,000Source | 74,561,000Source |
| Stockholders’ equity: | ||||||||||||
| Retained Earnings (Accumulated Deficit)USD | -607,448,000Source | -533,565,000Source | -692,975,000Source | -585,796,000Source | -494,476,000Source | -661,292,000Source | -565,740,000Source | -481,674,000Source | -631,260,000Source | -549,990,000Source | -468,706,000Source | -360,410,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 82,000Source | 87,000Source | -118,000Source | 20,000Source | -120,000Source | -70,000Source | -18,000Source | -125,000Source | 104,000Source | -23,000Source | -222,000Source | -912,000Source |
| Stockholders' Equity Attributable to ParentUSD | 171,415,000Source | 166,761,000Source | 235,161,000Source | 190,829,000Source | 112,272,000Source | 254,765,000Source | 207,345,000Source | 120,694,000Source | 261,185,000Source | 202,957,000Source | 129,441,000Source | 218,139,000Source |
| Additional Paid in Capital, Common StockUSD | 778,772,000Source | 700,232,000Source | 928,244,000Source | 776,596,000Source | 606,863,000Source | 916,117,000Source | 773,094,000Source | 602,488,000Source | 892,331,000Source | 752,961,000Source | 598,364,000Source | 579,456,000Source |
| Liabilities and EquityUSD | 242,839,000Source | 239,887,000Source | 312,135,000Source | 258,680,000Source | 185,502,000Source | 325,395,000Source | 273,308,000Source | 195,276,000Source | 334,164,000Source | 270,268,000Source | 225,099,000Source | 292,700,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 36,156,000Source | 36,413,000Source | 46,385,000Source | 31,723,000Source | 34,133,000Source | 39,045,000Source | 29,892,000Source | 31,373,000Source | 39,630,000Source | 31,126,000Source | 47,234,000Source | 33,131,000Source |
| Operating Lease, Liability, CurrentUSD | 6,900,000Source | 7,910,000Source | 6,931,000Source | 7,188,000Source | 7,858,000Source | 6,879,000Source | 7,472,000Source | 7,809,000Source | 6,892,000Source | 7,696,000Source | 7,761,000Source | 5,391,000Source |
| Accounts Payable, CurrentUSD | 11,147,000Source | 12,450,000Source | 16,005,000Source | 9,926,000Source | 9,936,000Source | 12,676,000Source | 7,914,000Source | 9,179,000Source | 12,989,000Source | 6,397,000Source | 14,920,000Source | 12,854,000Source |
| Operating Lease, Liability, NoncurrentUSD | 32,658,000Source | 35,601,000Source | 30,167,000Source | 33,390,000Source | 36,524,000Source | 31,023,000Source | 34,112,000Source | 37,434,000Source | 31,866,000Source | 34,882,000Source | 38,321,000Source | 41,041,000Source |
| Other Liabilities, NoncurrentUSD | 2,610,000Source | 1,112,000Source | 422,000Source | 2,738,000Source | 1,060,000Source | 562,000Source | 1,959,000Source | 3,022,000Source | 1,483,000Source | 1,303,000Source | 5,161,000Source | 389,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 1,471,000Source | — | — | 2,406,000Source | — | — | 1,126,000Source | — | — | 858,000Source | 1,700,000Source |
| Short-term InvestmentsUSD | 100,542,000Source | 67,851,000Source | 118,690,000Source | 119,858,000Source | 39,225,000Source | 159,624,000Source | 114,687,000Source | 51,438,000Source | 115,708,000Source | 93,594,000Source | 57,195,000Source | 78,530,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -30,032,000Source | -15,750,000Source | -81,270,000Source | -81,284,000Source | -108,296,000Source | -113,315,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 2,371,000Source | 2,587,000Source | 10,046,000Source | 10,941,000Source | 11,296,000Source | 8,432,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,553,000Source | 2,219,000Source | 9,429,000Source | 10,686,000Source | 14,051,000Source | 19,433,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -3,181,000Source | 2,833,000Source | 8,063,000Source | -9,590,000Source | 1,088,000Source | -1,825,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -809,000Source | 2,013,000Source | 4,550,000Source | -8,924,000Source | 5,178,000Source | 3,089,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -2,000Source | -1,000Source | 54,000Source | -31,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -22,478,000Source | -17,961,000Source | -74,946,000Source | -45,150,000Source | -56,258,000Source | -70,233,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -46,012,000Source | -22,542,000Source | -22,568,000Source | -35,069,000Source | 13,099,000Source | 52,537,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 3,192,000Source | 2,511,000Source | 4,504,000Source | 1,603,000Source | 10,911,000Source | 49,896,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 17,830,000Source | 20,087,000Source | 130,338,000Source | 114,672,000Source | 11,031,000Source | 1,366,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -50,651,000Source | -20,414,000Source | 32,830,000Source | 34,431,000Source | -32,144,000Source | -16,457,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | — | — | 23,000Source | 38,000Source | 64,000Source | 47,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 2,082,000Source | 2,677,000Source | 3,981,000Source | 2,830,000Source | 2,553,000Source | 2,219,000Source | 9,429,000Source | 10,686,000Source | 14,051,000Source | 19,433,000Source |
| Income Tax Expense (Benefit)USD | — | — | 3,000Source | 3,000Source | 5,000Source | 2,000Source | 16,000Source | 7,000Source | 21,000Source | 18,000Source | 83,000Source | 40,000Source |
| Investment Income, InterestUSD | — | — | 1,680,000Source | 1,384,000Source | 1,966,000Source | 1,878,000Source | 2,172,000Source | 2,027,000Source | 7,155,000Source | 5,510,000Source | 5,901,000Source | 2,396,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -21,652,000Source | -39,089,000Source | -31,683,000Source | -20,056,000Source | -30,032,000Source | -15,750,000Source | -81,270,000Source | -81,284,000Source | -108,296,000Source | -113,315,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | — | — | — | — | — | — | — | 5,565,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 26,000Source | -26,081,000Source | -16,000Source | -80,000Source | 20,000Source | -46,000Source | -142,000Source | -18,485,000Source | -4,068,000Source | 61,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 20,952,000Source | 17,782,000Source | 126,797,000Source | 30,079,000Source | 3,513,000Source | — |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 24,100,000Source | 44,250,000Source | 192,110,000Source | 88,000,000Source | 127,955,000Source | 223,923,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | — | — | 1,344,000Source | 2,465,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 14,495,000Source | 25,709,000Source | 22,357,000Source | 17,203,000Source | 15,472,000Source | 20,605,000Source | 69,648,000Source | 84,614,000Source | 73,481,000Source | 65,047,000Source |
| Cost of Goods and Services Sold | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 13,034,000Source | 11,444,000Source | 21,998,000Source | 14,179,000Source | 17,903,000Source | 12,263,000Source | 53,570,000Source | 46,187,000Source | 49,726,000Source | 63,969,000Source |
| Operating Income (Loss)USD | — | — | -23,291,000Source | -14,382,000Source | -33,591,000Source | -21,804,000Source | -32,161,000Source | -17,696,000Source | -88,057,000Source | -68,267,000Source | -109,936,000Source | -115,531,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 26,000Source | -26,081,000Source | -16,000Source | -80,000Source | 20,000Source | -46,000Source | -142,000Source | -18,485,000Source | -4,068,000Source | 61,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -21,649,000Source | -39,086,000Source | -31,678,000Source | -20,054,000Source | -30,016,000Source | -15,743,000Source | -81,249,000Source | -81,266,000Source | -108,213,000Source | -113,275,000Source |
| Income Tax Expense (Benefit)USD | — | — | 3,000Source | 3,000Source | 5,000Source | 2,000Source | 16,000Source | 7,000Source | 21,000Source | 18,000Source | 83,000Source | 40,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -21,652,000Source | -39,089,000Source | -31,683,000Source | -20,056,000Source | -30,032,000Source | -15,750,000Source | -81,270,000Source | -81,284,000Source | -108,296,000Source | -113,315,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.24Source | -0.64Source | -0.3Source | -0.23Source | -0.29Source | -0.18Source | -0.91Source | -1.37Source | -2.25Source | -2.48Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.24Source | -0.64Source | -0.3Source | -0.23Source | -0.29Source | -0.18Source | -0.91Source | -1.37Source | -2.25Source | -2.48Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 88,699,131Source | 61,051,350Source | 105,424,708Source | 88,517,498Source | 104,191,862Source | 87,463,885Source | 89,240,435Source | 59,251,013Source | 48,175,201Source | 45,704,805Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 88,699,131Source | 61,051,350Source | 105,424,708Source | 88,517,498Source | 104,191,862Source | 87,463,885Source | 89,240,435Source | 59,251,013Source | 48,175,201Source | 45,704,805Source |
| Additional Financial Items | ||||||||||||
| Costs and ExpensesUSD | — | — | 37,786,000Source | 40,091,000Source | 55,948,000Source | 39,007,000Source | 47,633,000Source | 38,301,000Source | 157,705,000Source | 152,881,000Source | 183,417,000Source | 180,578,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 23,000Source | 19,000Source | 29,000Source | 71,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 2,405,000Source | 2,758,000Source | 2,414,000Source | 2,531,000Source | 2,311,000Source | 2,587,000Source | 9,787,000Source | 10,941,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -81,312,000Source | -81,312,000Source | -106,833,000Source | -113,558,000Source |
| Interest ExpenseUSD | — | — | 64,000Source | 7,000Source | 37,000Source | 48,000Source | 47,000Source | 28,000Source | 205,000Source | 24,000Source | 110,000Source | 201,000Source |
| Investment Income, InterestUSD | — | — | 1,680,000Source | 1,384,000Source | 1,966,000Source | 1,878,000Source | 2,172,000Source | 2,027,000Source | 7,155,000Source | 5,510,000Source | 5,901,000Source | 2,396,000Source |
| Research and Development ExpenseUSD | — | — | 12,171,000Source | 11,683,000Source | 16,336,000Source | 12,381,000Source | 14,539,000Source | 12,640,000Source | 50,264,000Source | 48,905,000Source | 64,776,000Source | 64,912,000Source |
Offerings
Registration 333-295654
Filing attachments
psnl-ex99_1.htm · 8-K · 2026-11-04
Exhibit 99.1 Personalis Reports Third Quarter Results Reports Q3 clinical test volume of 13,157, clinical revenue of $4.4 million and overall revenue of $25.6 million FREMONT, Calif. - November 4, 2026 - Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial and operational results for the third quarter ended September 30, 2026. Recent Strategic and Operational Highlights ● Launched NeXT Personal® Real-Time Variant Tracker™: Commercia…
Read attachment ↗psnl-ex99_1.htm · 8-K · 2026-08-04
EX-99.1 2 psnl-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Personalis Reports Second Quarter Results and Recent Highlights Clinical test volume surged 199% year-over-year and 33% sequentially to 10,384 tests in Q2 Clinical revenue grew 442% to $2.6 million and overall revenue grew 30% year over year to $22.4 million Secured Medicare coverage for NeXT Personal® for IO monitoring and Neoadjuvant Breast Cancer monitoring to expand Medicare coverage to four indications FREMONT, Calif. - August…
Read attachment ↗d68794dex991.htm · 8-K · 2026-07-20
EX-99.1 2 d68794dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled Precision Oncology Platform Acquisition brings together Personalis’ MRD technology with Tempus’ commercial scale, multimodal data and AI platform to advance cancer monitoring, deepen insights and accelerate growth Expands Tempus’ reach across the cancer care continuum and accelerates access to industry-leading technology withi…
Read attachment ↗d89372dex45.htm · S-3ASR · 2026-05-07
Exhibit 4.5 PERSONALIS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20[•] Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗d89372dex47.htm · S-3ASR · 2026-05-07
Exhibit 4.7 P ERSONALIS, I NC. AND _____________, A S W ARRANT A GENT F ORM OF C OMMON S TOCK W ARRANT A GREEMENT D ATED A S O F __________ P ERSONALIS, I NC. F ORM OF C OMMON S TOCK W ARRANT A GREEMENT T HIS C OMMON S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between P ERSONALIS, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•]…
Read attachment ↗d89372dex48.htm · S-3ASR · 2026-05-07
Exhibit 4.8 P ERSONALIS, I NC. AND _____________, A S W ARRANT A GENT F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT D ATED A S O F __________ P ERSONALIS, I NC. F ORM OF P REFERRED S TOCK W ARRANT A GREEMENT T HIS P REFERRED S TOCK W ARRANT A GREEMENT (this “Agreement”), dated as of [•], between P ERSONALIS, I NC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust off…
Read attachment ↗